Kriya was founded on the idea that consolidating critical capabilities into one company would enable efficient, systematic delivery of new gene therapy products and technologies across multiple different problems, expanding the field's reach to tackle broader universal diseases. While a top-down approach of starting with a single asset and then figuring out how to manufacture it is typical, Kriya asserts that it is coming at gene therapy from the opposite end, building its manufacturing infrastructure and analytical platform to advance dozens of products . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge